Ozempic dose tiers explained: what the caption gets right and misses

What did @celebclinics actually say?

The creator described three Ozempic pens by color and dose: "the great one, which is the starter dose 0.25," a red one at 0.5 mg, and something "green and blueish" at 1 mg. They called this last one "the IS dosage" and promoted their clinic at the end. The video caption, meanwhile, describes a red-label pen for both 0.25 mg and 0.5 mg doses, and a blue-label pen for 1 mg. So the caption and the spoken transcript don't even agree with each other, which is already a problem.

The creator appears to be describing physical pen packaging from memory, possibly while holding the pens. But the color descriptions are muddled, the dose labeling is inconsistent between caption and speech, and calling the 1 mg dose "the IS dosage" is confusing and unexplained. Viewers trying to identify their own pens based on this video could easily walk away misinformed.

Does the science back this up?

The approved dose escalation schedule for Ozempic (semaglutide injection) is well-documented and not in dispute. What is in dispute is whether the color descriptions given here are accurate enough to be useful.

According to Novo Nordisk's prescribing information, Ozempic is available in three pen configurations: a 2 mg/1.5 mL pen that delivers 0.25 mg or 0.5 mg doses (used during the initiation phase), a 4 mg/3 mL pen delivering 1 mg doses, and a 8 mg/3 mL pen delivering 2 mg doses. The FDA label confirms these concentrations. The dose escalation protocol, per the SUSTAIN clinical trial program (Aroda et al., 2017, Diabetes Care), starts at 0.25 mg weekly for four weeks, then 0.5 mg, then optionally escalating to 1 mg or 2 mg based on glycemic response and tolerability. None of this is controversial. What the creator gets partially right is the existence of a starting dose and maintenance doses. What they get wrong is the pen color framing, which they present confidently but describe inconsistently.

What did they get wrong (or right)?

Let's give credit first. The 0.25 mg starting dose and the 0.5 mg and 1 mg maintenance doses are real. That part of the underlying clinical information is accurate. The dose escalation sequence they imply, starting low and moving up, reflects actual prescribing practice.

But here is what went wrong. First, the creator says "the great one" for the 0.25 mg pen, which is not standard terminology and suggests informal, potentially unreliable sourcing. Second, the 1 mg pen is described as "green and blueish" and called "the IS dosage," which is unclear and potentially garbled. Third, the caption posted alongside the video describes a red-label pen for both 0.25 mg and 0.5 mg, which actually aligns better with Novo Nordisk's labeling than what the creator said verbally, but the mismatch between caption and speech signals a lack of source rigor. Fourth, the video omits the 2 mg dose entirely, which has been FDA-approved since 2022 for type 2 diabetes. Leaving it out is not a small omission for a clinic-affiliated account presenting itself as an authoritative source.

What should you actually know?

If you are a patient trying to understand your Ozempic prescription, here is what actually matters. Ozempic pens are labeled by concentration, not just color, and the color coding can vary by country and manufacturing batch. Relying on pen color alone to identify your dose is not a safe practice.

The approved doses of Ozempic in the U.S. are 0.25 mg, 0.5 mg, 1 mg, and 2 mg, administered once weekly by subcutaneous injection. The 0.25 mg dose is a starting dose only and is not intended for long-term glycemic management. Per Novo Nordisk's current prescribing information and the SUSTAIN-6 trial (Marso et al., 2016, New England Journal of Medicine), dose escalation should be guided by a licensed prescriber based on tolerability and clinical response. No TikTok video, regardless of how many views it has, should substitute for that conversation. A clinic-affiliated creator has a higher responsibility to get this right, not lower. The pen color confusion in this video is the kind of detail that erodes patient trust in telehealth broadly.